Biofrontera Inc. to Report Second Quarter Financial Results on August 12, 2022
WOBURN, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2022 before the opening of the U.S. financial markets on Friday, August 12, 2022. The Company will hold a conference call that same day beginning at 11:00 a.m. Eastern time to discuss those results, provide a business update and answer questions.
Conference Call and Webcast Information
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.
LHA Investor Relations